Leeward Investments LLC MA Has $11.19 Million Holdings in Humana Inc. (NYSE:HUM)

Leeward Investments LLC MA decreased its position in shares of Humana Inc. (NYSE:HUM - Free Report) by 20.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 35,315 shares of the insurance provider's stock after selling 9,158 shares during the quarter. Leeward Investments LLC MA's holdings in Humana were worth $11,186,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. Creative Financial Designs Inc. ADV boosted its position in shares of Humana by 244.0% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider's stock worth $27,000 after acquiring an additional 61 shares in the last quarter. CarsonAllaria Wealth Management Ltd. boosted its holdings in shares of Humana by 111.4% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider's stock valued at $28,000 after purchasing an additional 39 shares in the last quarter. Atwood & Palmer Inc. bought a new position in shares of Humana in the 3rd quarter valued at $29,000. Your Advocates Ltd. LLP raised its holdings in shares of Humana by 81.8% during the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider's stock worth $32,000 after buying an additional 45 shares in the last quarter. Finally, Hantz Financial Services Inc. bought a new stake in shares of Humana during the 2nd quarter worth $35,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Trading Down 0.3 %

Shares of HUM stock traded down $0.75 during trading hours on Thursday, hitting $287.76. 2,397,810 shares of the company were exchanged, compared to its average volume of 1,873,047. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $527.18. The company has a 50 day simple moving average of $291.98 and a two-hundred day simple moving average of $333.24. The firm has a market cap of $34.65 billion, a P/E ratio of 25.56, a P/E/G ratio of 1.98 and a beta of 0.52.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, topping analysts' consensus estimates of $3.48 by $0.68. Humana had a net margin of 1.18% and a return on equity of 13.20%. The business had revenue of $29.30 billion during the quarter, compared to analysts' expectations of $28.66 billion. Equities analysts anticipate that Humana Inc. will post 16.15 EPS for the current year.

Humana Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be issued a $0.885 dividend. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.54 annualized dividend and a yield of 1.23%. Humana's payout ratio is currently 31.36%.

Analyst Upgrades and Downgrades

HUM has been the subject of several research analyst reports. Jefferies Financial Group downgraded Humana from a "buy" rating to a "hold" rating and lowered their target price for the stock from $519.00 to $253.00 in a research note on Monday, October 7th. Barclays upped their price objective on shares of Humana from $250.00 to $253.00 and gave the stock an "equal weight" rating in a research report on Thursday, October 31st. Stephens restated an "equal weight" rating and issued a $250.00 target price on shares of Humana in a research report on Wednesday, October 9th. Leerink Partners downgraded shares of Humana from an "outperform" rating to a "market perform" rating and lowered their price target for the stock from $400.00 to $250.00 in a report on Wednesday, October 2nd. Finally, Royal Bank of Canada cut their price objective on Humana from $400.00 to $265.00 and set an "outperform" rating on the stock in a report on Tuesday, October 8th. Twenty equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $315.86.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.